Ozanimod

Bulls have emerged in defense of Celgene Corporation (NASDAQ: CELG) as the sell-off continues after unfavorable news from the U.S. Food and Drug Administration. Both William Blair and Credit Suisse advised investors to keep buying. The Rating Credit Suisse analyst Alethia Young reiterated an...

Celgene Corporation (NASDAQ: CELG) is under continued stock pressure Wednesday after the U.S. Food and Drug Administration rejected its New Drug Application for ozanimod in the treatment of relapsing multiple sclerosis. Some bulls were undeterred by the sell-off, though. The Rating William Blair...

Celgene Corporation (NASDAQ: CELG) shares plummeted 10 percent Tuesday evening after the U.S. Food and Drug Administration rejected its New Drug Application for ozanimod in the treatment of relapsing multiple sclerosis. What Happened In a preliminary review, the FDA found that the clinical and...

Canaccord Genuity reiterated its Buy rating and $156 price target on Celgene Corporation (NASDAQ: CELG). In the report published Friday, the analysts stated their positive outlook for the near-term data readouts for Revlimid from REMARC and Otezla in Atopic Dermatitis. Additionally, they expect...

Celgene Corporation (NASDAQ: CELG) announced on Tuesday that it will be acquiring Receptos Inc (NASDAQ: RCPT) in a $7.3 billion deal. Robert Hugin, Celgene chairman and CEO, was on CNBC Wednesday to weigh in on the deal and its timing. Ozanimod: Key Driver "Exciting time for us and, I...

Shares of Receptos Inc (NASDAQ: RCPT) were trading higher by more than 10 percent during Wednesday's pre-market session after it received an acquisition offer on Tuesday by Celgene Corporation (NASDAQ: CELG) for $232 per share, valuing the entire transaction at $7.2 billion. Several of Wall...